OGRMF - Additional Revenue Growth Makes Organigram A Buy
With more than 60% stock returns delivered in about two months, Organigram (OGRMF) still seems undervalued. Other competitors are trading at larger capitalizations and are not reporting the same revenue growth. Additional stock returns could be expected if the shares are traded on the NASDAQ or the NYSE. In addition, a new brand is being released in 2019, which could lead to additional revenues. With all this in mind, this cannabis stock seems to be a great name to be followed closely in the following months.
Business
Organigram Holdings is based in New Brunswick and